Where Americans Actually Buy GLP-1s Now

Three years ago, getting Wegovy meant a prior authorization fight with your insurance company. In 2026 a large and growing share of Americans skip that entirely and buy the drug the way they buy anything else: at a posted price, from a manufacturer, a retailer or a telehealth app.

This article maps that channel shift, lists what each option charged in 2026, and flags the tradeoffs that do not show up on the price tag. Prices change frequently; treat every figure here as a dated snapshot and check the current price before you buy. Nothing here is medical advice or a recommendation of a specific provider.

What this page does not do. It contains no dosing guidance. It does not say what dose to take, how to change a dose, when to start or stop a medication, or how to combine one with another. Those are set by the FDA-approved prescribing information and Instructions for Use for each product, by your own prescription, and by the prescriber who wrote it. Prices and channels are a purchasing question; what and whether to take is a clinical one, and this page only addresses the first.

On naming products and sellers. Channels and prices are listed because they are the factual market; inclusion is not an endorsement, and the list is not exhaustive. Several of the named platforms are commercial sellers, and one of the price comparisons below comes from a publisher that earns affiliate revenue from some of the companies it compares. That is flagged where it appears.

How big is the cash channel?

Bigger than most people realize.

Novo Nordisk reported that for the week ending July 17, 2026, about 120,000 of roughly 310,000 weekly injectable Wegovy prescriptions in the US, about 39%, were filled in the self-pay channel through retail pharmacies, NovoCare Pharmacy and telehealth organizations [1].

For the Wegovy pill the share was higher still. IQVIA found that the majority of oral Wegovy volume flowed through cash-pay channels, and that about two-thirds of that volume came from people who had never taken any GLP-1 [2].

This happened for two reasons at once. Employers cut coverage, pushing patients out of the benefit. And manufacturers cut cash prices hard, pulling patients in.

What each channel charged in 2026

These figures are from 2026 reporting and manufacturer statements. Prices move; verify before you buy.

Manufacturer direct

Channel	Product	Price per month
LillyDirect	Zepbound KwikPen and single-dose vials	USD 299 to USD 449, with better pricing tied to refilling within 45 days [3]
LillyDirect	Zepbound 2.5 mg starter	USD 299 [4]
LillyDirect	Zepbound higher doses on schedule	USD 449 [3]
NovoCare Pharmacy	Wegovy injectable	about USD 199 introductory, stepping to about USD 349 [3]
NovoCare Pharmacy	Wegovy pill	USD 149 to USD 299 by dose [1]
Manufacturer cash	Foundayo	USD 149 to USD 349 by dose [5]

Gartner Consulting’s Jackie Swanson described LillyDirect’s refill-window pricing bluntly as “a loyalty program dressed as a discount schedule,” and NovoCare’s introductory-then-higher structure as “a classic acquisition funnel” [3]. That is not a criticism of the drugs; it is an accurate description of how the pricing is engineered.

Retail

Amazon. Amazon Pharmacy added the Zepbound KwikPen at USD 299 a month for the 2.5 mg starter dose on March 9, 2026, with cash prices visible before checkout [4][6]. It also sells Wegovy injectables and the Zepbound auto-injector with cash pricing starting at USD 299 a month [6]. In April 2026 Amazon launched a GLP-1 management program through Amazon One Medical, its primary care business, offering insured patients prices as low as USD 25 a month [3]. Same-day delivery reached nearly 3,000 US cities in 2026, expanding toward 4,500 by year end [6]. Amazon works with LillyDirect, WeightWatchers, UpScriptHealth and Noom on access [4].

Costco. Costco’s partnership with Sesame priced Wegovy at around USD 349 a month and requires a Costco membership [3]. As Swanson put it, “the prescription now helps sell the USD 65 card” [3].

Walmart. Walmart became a retail pickup point for LillyDirect, with prescriptions routed directly to LillyDirect’s self-pay pharmacy through the prescriber’s electronic health record [7]. In April 2026 Walmart expanded its Better Care Services digital platform to bundle GLP-1 prescriptions with nutrition coaching, fitness apps and AI coaching tools [3]. Walmart runs nearly 4,600 pharmacies and is the fifth-largest US prescription provider [3].

CVS. CVS participates in NovoCare and in the Medicare GLP-1 Bridge, and said that by early in the fourth quarter of 2026, eligible Zepbound and Foundayo patients would be able to see transparent pricing including cash-pay options in the CVS Health app for same-day pickup at its roughly 9,000 locations [8]. CVS also offers a USD 49 MinuteClinic virtual weight management visit [9].

Walgreens. Walgreens joined the Medicare GLP-1 Bridge and added weight management services to Walgreens Virtual Healthcare in February 2026, including on-demand follow-up visits by chat or video between 7 a.m. and 11 p.m. Central, seven days a week [9][10]. Walgreens’ chief pharmacy officer Rick Gates told NPR that stores stocked extra Wegovy, Zepbound and Foundayo ahead of the July 2026 Bridge launch, and that “there’s been a little bit more uptake than we even expected” [11].

Telehealth

Novo lists nine telehealth organizations distributing the Wegovy pill alongside more than 70,000 pharmacies [1]. In 2026 Novo introduced a subscription option in 3-, 6- or 12-month terms through Ro, WeightWatchers and LifeMD, with Hims & Hers and Sesame expected to come online [1].

Typical 2026 pricing, per Forbes Health’s comparison [12]. Note that Forbes Health is an affiliate-supported commercial comparison page, not an independent price survey, and these figures are a 2026 snapshot that has probably moved:

Platform	Membership	All-in monthly, oral GLP-1	All-in monthly, Wegovy
Ro	USD 149/month (Ro Body)	about USD 298	about USD 348
Hims & Hers	USD 149/month (USD 39 first month)	about USD 298	about USD 348
WeightWatchers Med+	about USD 74/month with 12-month commitment	about USD 273	about USD 423
Remedy Meds	none	about USD 299 (compounded semaglutide)	n/a

Ro CEO Zachariah Reitano told Sherwood News that “tens of millions of people were waiting on the sidelines for this improvement in form factor,” referring to the oral products, and that Ro had integrated with both Novo’s and Lilly’s direct-to-consumer pharmacies [13].

The compounded GLP-1 economy that these platforms were built on largely deflated in 2026. Compounded semaglutide cash prices ran roughly USD 149 to USD 397 a month and compounded tirzepatide roughly USD 278 to USD 524 [14], which is no longer a decisive advantage over FDA-approved products bought direct.

One row in the table above, Remedy Meds, is priced on compounded semaglutide rather than an FDA-approved product, and the distinction is not a technicality. Compounded drugs are not FDA-approved. The FDA does not review them for safety, effectiveness or quality before they are marketed, and the agency has published warnings about dosing errors with compounded semaglutide and about products using unapproved salt forms such as semaglutide sodium and semaglutide acetate. Both manufacturers’ shortage-era compounding pathways closed after FDA resolved the semaglutide and tirzepatide shortages. The price comparison is included because it is a real part of the market, not because the products are equivalent.

Medicare

If you have Medicare Part D and qualify, the Medicare GLP-1 Bridge offers Foundayo tablets, Wegovy injection or tablet, and the Zepbound KwikPen at a flat USD 50 monthly copay through December 31, 2027 [15]. Important limits: the copay does not count toward your Part D deductible or annual out-of-pocket cap, it cannot be reduced by Extra Help, and people prescribed a GLP-1 for type 2 diabetes or obstructive sleep apnea are not eligible because Part D should already cover those uses [15].

Why retailers want this business so badly

Because a GLP-1 refill is one of the very few genuinely recurring reasons an American walks into a store.

Eric Bormel of Solomon Partners told CNBC that “retailers are betting that if they can become the front door for obesity care, they’ll earn a relationship that extends far beyond a single GLP-1 prescription” [3]. Swanson made the structural point more sharply: “Pharmacy lock-in is loyalty-program economics applied to medicine, and it works because the refill, unlike almost everything else in retail, is non-negotiable” [3].

The economics favor scale. When a discount is tied to a network, the customer chooses their pharmacy at sign-up rather than at the counter [3]. That is a meaningful change for any pharmacy that historically won business through service and proximity.

For context, US retail pharmacy market share per Drug Channels Institute stands at roughly CVS 14.7%, Walgreens 14.6%, Walmart 4.8% [3]. The cash GLP-1 channel is the main tool Walmart and Amazon have to close that gap.

It is worth noting that large retailers have a poor record in healthcare. Walmart closed all 51 of its Walmart Health clinics in 2024; Amazon shut down Amazon Care at the end of 2022 and walked away from the Haven joint venture in 2021; CVS has shuttered many in-store MinuteClinics [3]. Kroger’s CEO said of GLP-1s back in 2023 that “sales dollars are a lot bigger than the margin dollars” [3].

The tradeoffs that are not on the price tag

Cash payments usually do not count toward your deductible or out-of-pocket maximum. If you have a high-deductible plan and expect other medical costs this year, paying cash for a GLP-1 can be cheaper monthly and worse annually. Check your plan.

Your pharmacy record fragments. This is the most concrete risk. Dared Price, who owns nine pharmacies in small Kansas towns, told CNBC: “If one of my customers wants to do a DTC program and has to go to CVS or Costco, those pharmacies don’t have access to the rest of their portfolio. My system won’t flag any drug interactions with GLP drugs and there are drug interactions that can be dangerous” [3]. He named insulin and oral contraceptives as examples.

CVS says its pharmacists are prepared to treat the whole patient, and senior executive Sid Tenneti noted that “access is only part of the equation with GLP-1 medications. Patients also need support to stay on therapy and see results” [3]. Both things can be true, and both are statements by companies with a commercial interest in the answer.

The underlying mechanism is not in dispute. Automated drug-interaction screening works by comparing a new prescription against the medication list a pharmacy can see; the FDA-approved labeling for semaglutide and tirzepatide products notes delayed gastric emptying and its potential to affect the absorption of concomitantly administered oral medicines, and the labeling advises monitoring in patients on oral medications with a narrow therapeutic index and on insulin or insulin secretagogues. A complete medication list held by the prescriber and dispensing pharmacist is what makes that screening possible. What to do about any specific combination is a question for them, not for this page.

The Medicare Bridge routes around your pharmacy of record. Bridge claims run through a single central processor rather than through your usual pharmacy’s system [3][15], which creates the same visibility gap.

Clinical support varies enormously. Elina Onitskansky, CEO of the obesity-care company Ilant Health, told CNBC that “the drugs are not the solution by themselves; they are a powerful tool. But the medication alone doesn’t work that well. People do much better when cared for by expert clinicians” [3]. She is describing an interested party’s view, but the underlying point about fragmentation is widely shared among obesity specialists.

Independent pharmacies are largely locked out. Price told CNBC that manufacturers “want to sign one contract and get 2,000 stores,” and that no comparable program exists for associations of independent pharmacies: “There are no good programs for independents. It is a travesty that there aren’t” [3].

How to compare options without getting lost

A practical sequence for comparing what things cost. None of these steps is a clinical instruction, and none of them should substitute for your prescriber and your plan:

1. Check what your plan covers first, including for the specific diagnosis on your prescription. GLP-1 coverage often differs between weight management and other approved indications.
2. If covered, compare your copay to the cash price. Copay cards from both manufacturers can bring commercially insured patients to as little as USD 25 a month, but they exclude Medicare and Medicaid.
3. If not covered, compare manufacturer direct against retail against telehealth. Watch for membership fees stacked on top of drug price, which is how telehealth totals reach USD 298 to USD 423.
4. Read the refill conditions. LillyDirect’s better pricing is conditioned on refilling within 45 days [3]. Missing that window can raise your price.
5. Read the introductory-period wording. Several 2026 prices were time-limited introductory offers that stepped up afterward [3].
6. Ask whether the program includes clinical follow-up. Some channels bundle a clinical evaluation and some are dispensing-only; that difference is a feature of the offering, and worth knowing before you choose.
7. Ask your pharmacist how they will see your full medication list if the GLP-1 is filled somewhere other than your usual pharmacy. Interaction screening depends on that list being complete, which is the point independent pharmacists have raised publicly [3].

Where this is going

Novo’s US list prices for Wegovy, Ozempic and Rybelsus drop to USD 675 a month on January 1, 2027 [16], the same day Medicare’s negotiated price of USD 274 for a 30-day supply takes effect [15]. List price matters even to cash payers because it anchors coinsurance and deductible-phase costs for insured patients, and it sets the ceiling that cash prices are measured against.

Meanwhile CVS Caremark restored Zepbound to its largest commercial formularies effective October 1, 2026 and unblocked Foundayo effective June 1, 2026 [17], which means insured access improved in the same year employer coverage contracted. The net effect is a market where the cheapest route genuinely differs person to person, and where checking the current price of three or four options is now a normal part of filling this prescription.

---

Sources

1. Novo Nordisk, “Financial report for the period 1 January 2026 to 30 June 2026,” August 4, 2026. https://attachment.news.eu.nasdaq.com/a0078e15b379bff5e3b0ffdbddb3d5075
2. IQVIA, “The outlook for obesity from 2026 to 2030,” April 21, 2026. https://www.iqvia.com/locations/emea/blogs/2026/04/the-outlook-for-obesity-from-2026-to-2030
3. CNBC, “Direct GLP-1 prescriptions are Walmart, Costco, Amazon weight-loss win,” August 1, 2026. https://www.cnbc.com/2026/08/01/glp-1-prescriptions-weight-loss-walmart-costco-amazon.html
4. HIT Consultant, “Amazon Pharmacy Adds Zepbound KwikPen to Its Same-Day Delivery for $299,” March 9, 2026. https://hitconsultant.net/2026/03/09/amazon-pharmacy-zepbound-kwikpen-glp1-299-same-day-delivery
5. Bloomberg Government, “Congress Takes Fresh Look at GLP-1 Legislation on Cost, Safety.” https://news.bgov.com/bloomberg-government-news/congress-takes-fresh-look-at-glp-1-legislation-on-cost-safety
6. Amazon, “Amazon One Medical introduces weight management program with upfront GLP-1 medication costs.” https://www.aboutamazon.com/news/retail/amazon-glp1-management-program
7. PharmExec, “Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients.” https://pharmexec.com/view/lilly-reduces-price-of-zepbound-single-dose-vials-for-self-pay-patients
8. Yahoo Finance, “CVS Health Enhances Its Direct-to-Consumer Weight Management Offerings.” https://finance.yahoo.com/healthcare/articles/cvs-health-enhances-direct-consumer-143000440.html
9. DistilInfo, “Walgreens Joins Medicare GLP-1 Bridge Drug Program,” June 26, 2026. https://distilinfo.com/2026/06/26/walgreens-joins-medicare-glp-1-bridge-drug-program
10. Business Wire, “Walgreens Virtual Healthcare Adds Weight Management Services,” February 26, 2026. https://www.businesswire.com/news/home/20260226251553/en/Walgreens-Virtual-Healthcare-Adds-Weight-Management-Services-to-Support-Patients-on-Their-Weight-Loss-Journey
11. NPR, “Medicare’s $50 obesity drug program is proving popular,” August 26, 2026. https://www.npr.org/2026/08/26/nx-s1-5940761/medicare-weight-loss-drugs
12. Forbes Health, “6 Cheapest Online Semaglutide Providers (2026).” https://www.forbes.com/health/weight-loss/cheapest-online-semaglutide-providers
13. Sherwood News, “How Novo Nordisk’s new Wegovy pill is transforming the weight-loss drug market.” https://sherwood.news/business/how-novo-nordisks-new-wegovy-pill-is-transforming-the-weight-loss-drug
14. GLP Chart, “Compounded GLP-1 by medication: which programs offer each (2026).” https://glpchart.com/compounded-glp1
15. National Council on Aging, “What Is the Medicare GLP-1 Bridge Program?” https://www.ncoa.org/article/expanding-access-to-weight-loss-medications-the-medicare-glp-1-bridge-program
16. Medscape / Reuters, “Novo Nordisk to Halve US List Price Of Wegovy From 2027,” February 24, 2026. https://www.medscape.com/s/viewarticle/novo-nordisk-slash-us-list-prices-ozempic-and-wegovy-wsj-2026a10005sl
17. CVS Health, “CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options,” May 28, 2026. https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html